Princess Ogbogu, MD
Allergy · Columbus, OHNPI 1992954390
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $109,188 of the $142,794 with a category attached, or 76.5%. 21 manufacturers reported payments, led by AstraZeneca at 25.0% of the total. Reporting peaked in 2020 at $43,598 and has fallen 61.9% since, to $16,627 in 2025.
Across 186 payments — averaging $767.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$36K
- Astrazeneca UK Limited$35K
- GSK$29K
- Sanofi$16K
- Biocryst Pharmaceuticals, Inc.$7K
- Novartis$7K
- plus $12K from 15 others
Across 68 payments — averaging $6558.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Blueprint Medicines Corporation$187K
- Astrazeneca UK Limited$167K
- GSK$80K
- Sanofi US Services Inc.$11K
- Novartis$440
What the payments were for
- Consulting fees$109,18876%
- Speaking & faculty fees$1,4851%
- Grants$3,0002%
- Travel & lodging$24,17417%
- Food & beverage$4,9473%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 44 | $35,770 |
| Astrazeneca UK Limited | 24 | $34,983 |
| GSK | 28 | $29,300 |
| Sanofi | 19 | $16,197 |
| Biocryst Pharmaceuticals, Inc. | 15 | $7,131 |
| Novartis | 17 | $6,968 |
| Genentech USA, Inc. | 9 | $6,095 |
| Astrazeneca AB | 2 | $3,702 |
| Blueprint Medicines Corporation | 1 | $1,485 |
| Biocryst US Sales Co., LLC | 3 | $217 |
| CSL Behring | 4 | $186 |
| Optinose US, Inc. | 4 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $125 |
| Pharming Healthcare, Inc. | 1 | $125 |
| Aquestive Therapeutics, Inc. | 1 | $119 |
| Regeneron Healthcare Solutions, Inc. | 3 | $89 |
| Grifols USA, LLC | 2 | $44 |
| Pfizer | 1 | $33 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Jubilant Hollisterstier LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 23 | $62,951 |
| Dupixent PenDupilumab | 15 | $56,876 |
| Epinephrine | 25 | $8,831 |
| Azelastine Hcl | 100 | $3,847 |
| Mometasone Furoate | 25 | $3,088 |
| Fluticasone Propionate | 93 | $1,167 |
| Levocetirizine Dihydrochloride | 64 | $1,054 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $441 |
Paid to pharmacies, not to this prescriber.
Other allergy in Columbus
- Casey CurtisColumbus$2K
- Tiffany OwensColumbus$116
- Roger FriedmanWesterville$155K
- Mehmet BasaranWesterville$8K
- Kara WadaDelaware$8K
- Asif KhanYoungstown$5K
- Barry LamplBeachwood$5K
- Terri McMillanCincinnati$3K
- Ronald StraussFairview Park$700
- Gregory WattsCleveland$535
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.